IP Library › Granted Patent US 12,344,589
Granted Patent B2
US 12,344,589 · App. 17/639,296 · Granted Jul 1, 2025

Method for producing a 1,5-benzothiazepin compound

Inventors: Shinya Kiguchi (Izumo, JP); Ganapati G. Bhat (Bangalore, IN); Johnson M. Coutinho (Bangalore, IN); Mikael Dahlstrom (Mölndal, SE); Michael Lofthagen (Stockholm, SE); Akinori Tatara (Kanagawa, JP)
Assignee: ELOBIX AB
C07D281/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,589
App. No.
17/639,296
Granted
Jul 1, 2025
Kind
B2
Abstract

The present invention relates to a process for the preparation of a compound of formula (I) comprising: reacting a compound of formula (II) with a compound of formula (III) in the presence of a triazine compound to obtain a compound of formula (IV), and deprotecting said compound of formula (IV) to obtain the compound of formula (I). The compound of formula (I) can be prepared by the process according to the present invention in high yields and high purity. In addition, the process according to the present invention does not use a large amount of solvents or require a purification process of intermediate compounds.

Claims (52)

1. A process for the preparation of a compound of formula (I):

wherein

R 1 and R 2 are each independently C 1-4 alkyl;

R 3 is C 1-4 alkyl;

R 4 is selected from the group consisting of hydrogen, hydroxy, halo, nitro, cyano and C 1-4 alkyl; and

R 5 is selected from the group consisting of hydrogen, hydroxy, halo, nitro, cyano and C 1-4 alkyl;

comprising reacting a compound of formula (II)

wherein R 1 , R 2 , R 3 , and R 4 are each as defined above,

with a compound of formula (III) in the presence of a triazine compound:

wherein

R 5 is as defined above; and

R 6 is a protecting group;

to obtain a compound of formula (IV):

wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each as defined above,

and deprotecting said compound of formula (IV) to obtain the compound of formula (I).

2. The process according to claim 1 , wherein the triazine compound is selected from the group consisting of 2,4,6-trichloro-1,3,5-triazine (TCT), 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), 2,4-dichloro-6-methoxy-1,3,5-triazine (DCMT), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM), and a mixture thereof.

3. The process according to claim 1 , wherein R 1 and R 2 are each n-butyl.

4. The process according to claim 1 , wherein R 3 is methyl.

5. The process according to claim 1 , wherein R 4 and R 5 are each hydrogen.

6. The process according to claim 1 , wherein R 6 is selected from the group consisting of C 1-4 alkyl and trisubstituted silyl.

7. The process according to claim 1 , wherein R 6 is tert-butyl.

8. The process according to claim 1 , wherein the compound of formula (IV) is deprotected by reacting with trifluoroacetic acid.

9. The process according to claim 1 , wherein the step of deprotecting said compound of formula (IV) is performed in the presence of toluene and water, and the amount of water used is 0.2 to 2.0% by weight with respect to the amount of toluene.

10. The process according to claim 1 , wherein the compound of formula (I) is precipitated from a solution by the addition of heptane.

11. The process according to claim 1 , wherein the compound of formula (II) is prepared by an alkylation reaction comprising reacting a compound of formula (V):

wherein

R 1 and R 2 are each independently C 1-4 alkyl;

R 3 is C 1-4 alkyl; and

R 4 is selected from the group consisting of hydrogen, hydroxy, halo, nitro, cyano and C 1-4 alkyl;

with a compound of formula (VI) in the presence of water:

wherein

R 7 is a protecting group; and

X is a leaving group;

to obtain an intermediate compound of formula (VII):

wherein R 1 , R 2 , R 3 , R 4 , and R 7 are each as defined above,

followed by hydrolysis of the ester R 7 O—C(O)—,

to obtain the compound of formula (II).

12. The process according to claim 11 , wherein R 7 is selected from the group consisting of C 1-4 alkyl and C 1-4 haloalkyl.

13. The process according to claim 11 , wherein X is selected from the group consisting of halo, trifluoromethanesulfonate, methanesulfonyl and p-toluenesulfonyl.

14. The process according to claim 11 , wherein the preparation of the intermediate compound of formula (VII) is performed in toluene.

15. The process according to claim 11 , wherein the amount of water used in the reaction of the compound of formula (V) with the compound of formula (VI) is 0.01 to 0.5% by weight with respect to the amount of the compound of formula (V).

16. The process according to claim 11 , wherein the intermediate compound of formula (VII) is not isolated and used directly in the next step.

17. The process according to claim 11 , wherein the alkylation reaction and the subsequent hydrolysis reaction are performed in the same solvent.

18. The process according to claim 1 , wherein the compound of formula (III) is prepared by deprotecting a compound of formula (VIII) in the presence of a solvent of alcohol having 3 or more carbon atoms:

wherein

R 5 is selected from the group consisting of hydrogen, hydroxy, halo, nitro, cyano and C 1-4 alkyl; and

R 6 is a protecting group.

19. The process according to claim 18 , wherein the alcohol having 3 or more carbon atoms is selected from the group consisting of 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, and a mixture thereof.

20. The process according to claim 1 , further comprising transforming the compound of formula (I) into a stable crystalline hydrate of formula (I).

21. The process according to claim 20 , wherein the compound of formula (I) is dissolved in ethyl acetate.

22. The process according to claim 21 , wherein n-heptane is added to the solution of the compound of formula (I) in ethyl acetate.

23. The process according to claim 20 , wherein the stable crystalline hydrate is a crystalline monohydrate.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: KIGUCHI, SHINYA; TATARA, AKINORI
To: EA PHARMA CO., LTD
Reel/Frame 061516/0892 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: BHAT, GANAPATI G.; COUTINHO, JOHNSON M.
To: SYNGENE INTERNATIONAL LTD
Reel/Frame 061517/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: DAHLSTROM, MIKAEL
To: ASTRAZENECA AB
Reel/Frame 061517/0751 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: LOFTHAGEN, MICHAEL
To: ARDENA SÖDERTÄLJE AB
Reel/Frame 061518/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: EA PHARMA CO., LTD
To: ELOBIX AB
Reel/Frame 061518/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: SYNGENE INTERNATIONAL LTD
To: ELOBIX AB
Reel/Frame 061518/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: ASTRAZENECA AB
To: ELOBIX AB
Reel/Frame 061518/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: ARDENA SÖDERTÄLJE AB
To: ELOBIX AB
Reel/Frame 061518/0638 →
Priority Claims (2)
IN 201911036177 · Sep 9, 2019 · national
JP 2019-205580 · Nov 13, 2019 · national
Continuity (1)
Related Publication 20220315547A1 · Oct 6, 2022
References Cited (27)
US 7192946B2 · Starke et al. · 2007 [cited by applicant]
US 10428109B1 · Bhat et al. · 2019 [cited by applicant]
US 10995115B2 · Bhat et al. · 2021 [cited by applicant]
US 20170143738A1 · Ando et al. · 2017 [cited by applicant]
US 20170143783A1 · Ando et al. · 2017 [cited by applicant]
US 20200109165A1 · Bhat et al. · 2020 [cited by applicant]
JP 2004516285 · 2004 [cited by applicant]
JP 2004521961 · 2004 [cited by applicant]
JP 2016522181 · 2016 [cited by applicant]
JP 2017537061 · 2017 [cited by applicant]
WO WO200166533 · 2001 [cited by applicant]
WO WO200250051 · 2002 [cited by applicant]
WO WO2003020710 · 2003 [cited by applicant]
WO WO2003022286 · 2003 [cited by applicant]
WO WO2003022825 · 2003 [cited by applicant]
WO WO2003091232 · 2003 [cited by applicant]
WO WO2003106482 · 2003 [cited by applicant]
WO WO2004089350 · 2004 [cited by applicant]
WO WO2012064266 · 2012 [cited by applicant]
WO WO2014174066 · 2014 [cited by applicant]
WO WO2016062848 · 2016 [cited by applicant]
Dunetz et al., “Large-Scale Applications of Amide Coupling Reagents for the Synthesis of Pharmaceuticals,” Organic Process Research & Development, 2016, 20(2):140-177. [cited by applicant]
Kunishima et al., “Synthesis and Application Development for Novel Triazine Dehydration Concentration Agent,” Wako Pure Medicine Times, Nov. 2003, 72(2):8-11. [cited by applicant]
PCT International Preliminary Report on Patentability in International Application No. PCT/JP2020/032378, dated Mar. 9, 2022, 9 pages (with English translation). [cited by applicant]
PCT International Search Report and Written Opinion in Application No. PCT/SE2019/050208, dated Jul. 8, 2019, 15 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/JP2020/032378, dated Oct. 20, 2020, 19 pages (with English translation). [cited by applicant]
SE Search Report in Swedish Application No. 1850474-6, dated Oct. 11, 2018, 3 pages. [cited by applicant]